HLA-C and breast carcinoma: Although Day-2 ‘rapid DCs’ have been demonstrated to be able to stimulate antigen-specific response in breast cancer patients when loaded with tumor-associated peptides [15], no antigen processing is necessary under these circumstances, since the immunodominant peptides can bind directly to the MHC molecules that are expressed on the DCs.